Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib Roll-over Study for Patients from Previous Novartis Trials
NCT07456891Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Apr 2026
- Primary completion
- Jan 2033
- Countries
- 9
01
Overview
Phase 3, open-label trial of remibrutinib in Dermatopathy and allergic disease (2 arms), sponsored by Novartis. Primary endpoint: Number of participants with the occurrence of Adverse Events or Serious Adverse Events at 7 years. Started Apr 2026; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
Dermatopathyallergic disease
Beyond the preview
Go deeper on NCT07456891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07456891.